

SUPPLEMENTAL MATERIAL

Supplementary table I – Comparison of included participants vs. those excluded (missing ACR)

	Included in the analysis (n=8,913)	Excluded (missing ACR) (n=448)	<i>P</i> value
Age (years)	67.9 ± 9.4	67.3 ± 8.8	0.14
Female sex (n, %)	3147 (35.3%)	185 (41.3%)	0.01
Race or ethnic group (n, %)			
Non-Hispanic white	5116 (57.4%)	283 (63.2%)	0.033
Non-Hispanic black	2690 (30.2%)	112 (25.0%)	
Hispanic	943 (10.6%)	41 (9.2%)	
Other	164 (1.8%)	12 (2.7%)	
Baseline blood pressure (mmHg)			
Systolic	139.7 ± 15.6	139.1 ± 15.1	0.47
Diastolic	78.1 ± 12.0	78.2 ± 11.1	0.89
Antihypertensive agents (n)	2.0 (1.0-3.0)	2.0 (1.0-2.0)	0.13
Cardiovascular disease (n, %)	1,804 (20.2%)	73 (16.3%)	0.042
Body mass index (kg/m ²)	29.9 ± 5.8	29.3 ± 5.4	0.033
Fasting plasma glucose (mg/dL)	98.9 ± 13.6	97.6 ± 11.7	0.055
Fasting total cholesterol (mg/dL)	189.9 ± 41.1	194.3 ± 43.2	0.03
Fasting HDL cholesterol (mg/dL)	52.8 ± 14.5	54.0 ± 13.4	0.087
Fasting total triglycerides (mg/dL)	107.0 (77.0-150.0)	99.0 (72.0-139.0)	0.007
Statin use (n, %)	3,893 (44.0%)	161 (37.6%)	0.01
Aspirin use (n, %)	4,540 (51.0%)	216 (50.3%)	0.79
Current smoker (n, %)	3797 (42.6%)	176 (39.3%)	0.166
eGFR (mL/min/1.73 m ²)	71.6 ± 20.7	74.4 ± 18.5	0.007
Chronic kidney disease - n (%)	2,554 (28.7%)	92 (20.5%)	<0.001

ACR, albumin-to-creatinine ratio; eGFR, estimated glomerular filtration rate; HDL, High-density lipoprotein.

Supplementary table II - Association of albuminuria with secondary outcomes

	Categorical analysis		Continuous analysis
	No albuminuria (n=7183)	Albuminuria (n=1730)	LogACR (n=8913)
	No. Events/Pts	No. Events/Pts	HR (95% CI)
Myocardial infarction			
No. Events/Pts	136/7110 (1.9%)	72/1694 (4.3%)	208/8804 (2.4%)
Unadjusted HR	Ref.	2.28 (1.71-3.05)	1.29 (1.17-1.42)
Adjusted HR	Ref.	1.95 (1.43-2.66)	1.20 (1.08-1.34)
Other ACS			
No. Events/Pts	60/7110 (0.8%)	18/1693 (1.1%)	78/8803 (0.9%)
Unadjusted HR	Ref.	1.32 (0.77-2.26)	1.15 (0.97-1.37)
Adjusted HR	Ref.	1.18 (0.67-2.08)	1.10 (0.91-1.33)
Heart failure			
No. Events/Pts	85/7110 (1.2%)	75/1696 (4.4%)	160/8806 (1.8%)
Unadjusted HR	Ref.	3.61 (2.63-4.97)	1.65 (1.50-1.82)
Adjusted HR	Ref.	2.57 (1.81-3.63)	1.47 (1.32-1.65)
Cardiovascular death			
No. Events/Pts	59/7115 (0.8%)	40/1697 (2.4%)	99/8812 (1.1%)
Unadjusted HR	Ref.	2.95 (1.95-4.46)	1.62 (1.43-1.83)
Adjusted HR	Ref.	1.87 (1.18-2.96)	1.44 (1.25-1.66)
Composite CV outcome			
No. Events/Pts	356/7116 (5.0%)	193/1698 (11.4%)	549/8814 (6.2%)
Unadjusted HR	Ref.	2.32 (1.94-2.77)	1.40 (1.32-1.48)
Adjusted HR	Ref.	1.86 (1.54-2.25)	1.30 (1.22-1.39)

Adjusted model: age, sex, race, smoking status, systolic BP, antihypertensive agents, prior cardiovascular disease (CVD), body mass index, estimated glomerular filtration rate (eGFR), triglycerides, total cholesterol, HDL cholesterol, plasma glucose, statin use, aspirin use, and randomized treatment arm.

HR, hazard ratio; CI, confidence interval; ACR, urinary albumin-to-creatinine ratio; ACS, acute coronary syndrome, CV, cardiovascular. Ref., reference category.

Supplementary table III - Association of albuminuria with myocardial infarction and heart failure according to randomized treatment arm

	Standard treatment arm		Intensive treatment arm	
	No albuminuria (n=3588)	Albuminuria (n=873)	No albuminuria (n=3595)	Albuminuria (n=857)
Myocardial infarction				
No. Events/Pts	56/3559 (1.6%)	39/858 (4.5%)	80/3551 (2.3%)	33/836 (3.9%)
Unadjusted HR	Ref.	2.97 (1.94-4.53)	Ref.	1.72 (1.13-2.62)
Adjusted HR	Ref.	2.59 (1.62-4.12)	Ref.	1.52 (0.98-2.38)
Heart failure				
No. Events/Pts	26/3559 (0.7%)	35/859 (4.1%)	59/3551 (1.7%)	40/837 (4.8%)
Unadjusted HR	Ref.	5.66 (3.32-9.64)	Ref.	2.82 (1.86-4.28)
Adjusted HR	Ref.	4.24 (2.32-7.74)	Ref.	1.96 (1.24-3.09)

Adjusted model: age, sex, race, smoking status, systolic BP, antihypertensive agents, prior cardiovascular disease (CVD), body mass index, estimated glomerular filtration rate (eGFR), triglycerides, total cholesterol, HDL cholesterol, plasma glucose, statin use, aspirin use.

HR, hazard ratio; CI, confidence interval. Ref., reference category.